Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I AM 1.2 million shares VOTING NO FOR R/'S =No lawers change my mined =because (CYTR)
shares worth at list $4.80 a share not a $0.58 a share like incompetent management think.
$1.10 end of the week -CytRx will receive up to $356 Million from NantCell Under the terms of the license agreement,
SELL-SELL-SELL GET MONEY AND RUN
I recommend Strong BUY (CYTR) Please read my recommendation to other companies I was 98% right.
No need to R/S -(CYTR) will reach $1.10 a share after FDA news which coming any time.
NASDAQ =after appeal granted 180 days extensions to (CYTR) starting from August 28,2017 Bullish
No need to R/S -(CYTR) will reach $1.10 a share after FDA news which coming any time.
I am buying additional shares every day , Good luck to all .
No shirts in penny stocks it is just fake thinking. .
Do not listen bed looser who sold their shares on this board in lost .
I recommend Strong BUY Please read my recommendation to other companies I was 98% right.
NASDAQ granted 180 days extensions from August 28,2017 Bullish
Majority shareholders VOTED NO for R/S
Under the terms of the license agreement, NantCell made a strategic investment by purchasing $13 million of CytRx common stock at $1.10 per share, representing approximately a 92% premium to CytRx's most recent market price.
CytRx will receive up to $356 Million in a Strategic Investment and Milestones in Addition to Royalties
Under the terms of the license agreement, NantCell made a strategic investment by purchasing $13 million of CytRx common stock at $1.10 per share, representing approximately a 92% premium to CytRx's most recent market price. CytRx is entitled to receive up to an additional $343 million in milestone payments related to regulatory approvals and commercial milestones for aldoxorubicin. In addition, CytRx will receive increasing double-digit royalties for sales of aldoxorubicin for soft tissue sarcomas and mid to high single digit royalties for all other indications. NantCell will be responsible for all future development, manufacturing and commercialization expenses. CytRx also issued NantCell a warrant to purchase up to 3 million shares of common stock at $1.10 over the next 18 months.
http://www.nasdaq.com/press-release/cytrx-corporation-announces-global-strategic-license-with-nantcell-inc-for-aldoxorubicin-an-albumi-20170728-00682
CYTR has a chance to add $3.53 or 751.06% in 52 weeks, based on mean target price ($4) placed by analysts.
Majority shareholders VOTED NO for R/S =
NASDAQ granted 180 days extensions from August 28,2017 Bullish
$CYTR Majority shareholders VOTED NO for R/S =NASDAQ granted 180 days extensions from August 28,2017 Bullish
STRONG BUY =GOOD NEWS COMING ANY TIME FROM FDA -NO R/S =At recent closing price of $0.47, CYTR has a chance to add $3.53 or 751.06% in 52 weeks, based on mean target price ($4) placed by analysts.
(DCTH) going to $.08- $0.04 Sorry- How meany times I recommend SELL-SELL-SELL-- Delcath Announces Relisting on OTCQB
Pre-Market Ask $1.50-NIH-funded International Diabetes Closed Loop (IDCL) Trial to Combine Technologies from Tandem Diabetes Care, Dexcom and TypeZero
http://www.businesswire.com/news/home/20161110005485/en/NIH-funded-International-Diabetes-Closed-Loop-IDCL-Trial'
Tandem Diabetes Care Inc (TNDM) Receives $5.08 Consensus Target Price from Brokerages
Posted by Stefani Robinson on Sep 10th, 2017 //
https://www.truebluetribune.com/2017/09/10/tandem-diabetes-care-inc-tndm-receives-5-08-consensus-target-price-from-brokerages.html
andem Diabetes Care Inc (TNDM) Receives $5.08 Consensus Target Price from Brokerages
Posted by Stefani Robinson on Sep 10th, 2017 //
https://www.truebluetribune.com/2017/09/10/tandem-diabetes-care-inc-tndm-receives-5-08-consensus-target-price-from-brokerages.html
ALERT = I SAY 1:500 R/S APPROVED no news insiders just selling block shares before shares fall to $0.02 Bearish
Tandem Diabetes Care Inc (TNDM) Receives $5.08 Consensus Target Price from Brokerages
Posted by Stefani Robinson on Sep 10th, 2017 //
https://www.truebluetribune.com/2017/09/10/tandem-diabetes-care-inc-tndm-receives-5-08-consensus-target-price-from-brokerages.html
$DCTH ALERT-COULD R/S HAS BEEN APPROVED -CAUTIOUS/// Bearish
BUY ALERT! R/S NOT BE USED TILL JUNE 20.2018 or to be consoled 180 days directions Nasdaq gives to (TNDM) read 8k filings below //
sProposal 1 : To approve an amendment to our certificate of incorporation to effect a reverse stock split of our issued and outstanding common stock at a ratio not less than 1-for-8 and not greater than 1-for-12, with the exact ratio to be set within that range at the discretion of our board of directors before June 20, 2018 without further approval or authorization of our stockholders.
(The board of directors may alternatively elect to abandon such proposed amendment and not effect the reverse stock split authorized by our stockholders, in its sole discretion.)
https://ih.advfn.com/p.php?pid=nmona&article=75603770
STRONG BUY! NEWS! FDA approved to commercialize a Tandem Diabetes Care
$1.85 = STRONG BUY! NEWS! FDA approved to commercialize a Tandem Diabetes Care Inc t:slim X2 Insulin Pump with Dexcom G5 Mobile integration.-Current Report Filing (8-k)
$ABIL Opening pre-market at $1.50 a share . In Tel-Aviv shares up 10.3% Good indication
$ABIL In Tel-Aviv shares up 10.3% Good indication re 2q As of 04/09/2017 12:14 pointing out Opening pre-market at 05/09/2017 $1.50 a share .
STRONG BUY! FDA approval and commercial launch of the t:slim X2 Insulin Pump with Dexcom G5 Mobile integration.-Current Report Filing (8-k) August 28, 2017
Ability Inc. Regains Compliance with NASDAQ Listing Rule https://finance.yahoo.com/news/ability-inc-regains-compliance-nasdaq-120000847.html
Strong Buy going over $1.10
SELL ALERT! UNXL file petition for relief under the U.S. Bankruptcy
UniPixel, Inc. Announces Form 8-K Filing Today
Date : 08/25/2017 @ 5:27PM
Source : PR Newswire (US)
Stock : Uni-Pixel, Inc. (MM) (UNXL)
Quote : 0.1292 0.0 (0.00%) @ 5:19AM
UniPixel, Inc. Announces Form 8-K Filing Today
Print
Alert
Uni-Pixel, Inc. (MM) (NASDAQ:UNXL)
Historical Stock Chart
1 Month : From Jul 2017 to Aug 2017
Click Here for more Uni-Pixel, Inc. (MM) Charts.
SANTA CLARA, Calif., Aug. 25, 2017 /PRNewswire/ -- UniPixel, Inc. (NASDAQ: UNXL) has today filed a Form 8-K announcing a number of actions.
On August 24, 2017, the board of directors of UniPixel, authorized the company to file a voluntary petition for relief under the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Northern District of California. The petition has not yet been filed but it is anticipated that the company will do so in the next 1-2 business days. It is also currently anticipated that the company will file the petition under Chapter 11 of the Bankruptcy Code which would enable it to act as "debtor-in-possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. The company has retained the McNutt Law Group LLP as its counsel.
As had been stated by the company, it is obligated to advance expenses for the defense of its two former executive officers, Reed Killion and Jeffrey Tomz, in their defense on an action brought against them by the Securities and Exchange Commission. A year ago, on August 22, 2016, Messrs. Killion and Tomz filed an action against the company for advancement of expenses in the Delaware Chancery Court. The company disputed a portion of the expenses incurred in 2016 as unreasonable, but has since been ordered to pay some of those disputed fees. In addition, only a portion of expenses incurred in 2017 have been advanced as of this time. The company and Messrs. Killion and Tomz have been in discussions regarding timing of payment of advancement of expenses, but have been unable to reach a resolution and Messrs. Killion and Tomz have moved to seek recourse in the Delaware Chancery Court, including seeking to have the company liquidate assets to provide funds for the advancement of expenses. In light of this, the company intends to use the bankruptcy process to seek to sell the assets of the company including manufacturing equipment, R&D equipment, intellectual property assets, individually or to an interested buyer in totality and subject to the approval of the Bankruptcy Court.
In addition, all the directors of the Company other than Jeff Hawthorne resigned effective August 24, 2017, and on August 25, 2017, the Company terminated the employment of all employees, including Mr. Hawthorne and the other officers of the company.
About UniPixel
UniPixel, Inc. (NASDAQ: UNXL) develops and markets high performance metal mesh capacitive touch sensors for the touchscreen and flexible displays markets. The Company's roll-to-roll electronics manufacturing process patterns fine line conductive elements on thin films. The company markets its technologies for touch panel sensor, cover glass replacement, and protective cover film applications under the XTouch™ and Diamond Guard™ brands. For further information, visit www.unipixel.com.
https://ih.advfn.com/p.php?pid=nmona&article=75522952
(DCTH)' will file the petition under Chapter 11 of the Bankruptcy?
SELL ALERT! UNXL file for Bankruptcy On August 24, 2017, the board of directors of UniPixel, authorized the company to file a voluntary petition for relief under the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Northern District of California.
BUY ALERT!-(CERC) Major Shareholder Acquires $8296377 Stock at market August 29 2017 look 8k today Bullish
https://www.dispatchtribunal.com/2017/08/29/cerecor-inc-cerc-major-shareholder-acquires-82963-77-in-stock.html
Zacks=Our valuation currently stands at $1.50. CERC
CERC: Sells CERC-501 for $25 Million; Company Currently Trading Below Cash Value
Zacks Small Cap Research
By David Bautz, PhD
Conclusion and Valuation
Following disappointing clinical results for both CERC-301 and CERC-501, the company is looking to “start anew” with a large amount of cash, a renewed focus on the pipeline, and the hiring of a new CEO. We are looking forward to learning more about the use of CERC-301 in orphan neurological indications, and what those indications might be. We anticipate the company moving ahead with an investigational new drug (IND) application for CERC-611 to begin development as an adjunctive treatment for seizures in patients with epilepsy, and additional details about the clinical path forward after that occurs. We anticipate CERC-406 is at least a couple of years away from the clinic as it is still early in preclinical development.
We estimate Cerecor currently has approximately $28 million in cash and a market cap of approximately $15 million. We see no reason the stock should be trading below cash, and CERC-611 has some intriguing preclinical data to support its development as a treatment for seizures. Our valuation currently stands at $1.50.
http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2017/CERC-Sells-CERC-501-for-25-Million-Company-Currently-Trading-Below-Cash-Value-article/default.aspx
Strong Buy going over $1.10
NEWS=Pareteum Corporation (AMEX:TEUM) Technicals Update
https://buckeyebusinessreview.com/2017/08/23/stock-notebook-pareteum-corporation-amexteum-technicals-update/
TEUM STRONG BUY=company singed new $2.4 million contract
CAPR Getting Voucher from FDA any day Strong Buy! Bullish
PLEASE READ CORRECTLY -
On August 15, 2017 ( Not August 14, 2017) DCTH received written notification from the Listing Qualifications Staff of The NASDAQ
REPLY BY DCTH =The Company intends to timely request a hearing before the Panel, which request will stay any suspension or desisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires.
SO DCTH TIMELY REQUESTED HEARING
On August 15, 2017, Delcath Systems, Inc, Inc. (the “Company”) received written notification from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s continued non-compliance with the minimum stockholder’s equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”), the Staff had determined to delist the Company’s securities from Nasdaq (the “Staff Determination”) unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”).
SO DCTH TIMELY REQUESTED HEARING
The Company intends to timely request a hearing before the Panel, which request will stay any suspension or delisting action by Nasdaq at least until the hearing process concludes and any extension granted by the Panel expires. At the hearing, the Company will present its plan to evidence compliance with the Rule, and request an extension of time within which to do so.